Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

BD Diagnostic Systems — Predicate Candidate Screening

6 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

49 daysmedian FDA review time
125 days90th percentile
6clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K260213BD BACTEC FXI Culture SystemBD Diagnostic Systems2026-05-281250
K032518PASCO MIC AND MIC/ID PANELS, GEMIFLOXACIN (STREP)Bd Diagnostic Systems2003-09-15320
K032153BD PHOENIX AUTOMATED MICROBIOLOGY SYSTEM CEFOTAXIME 0.5-64 UBd Diagnostic Systems2003-09-11590
K032259PASCO MIC AND MIC/ID PANELSBd Diagnostic Systems2003-08-19280
K031429BD PHOENIX AUTOMATED MICROBIOLOGY SYSTEM-MEROPENEM 0.25-16 UBd Diagnostic Systems2003-06-06310
K030091BD PHOENIX AUTOMATED MICROBIOLOGY SYSTEM - NORFLOXACIN 0.25 Bd Diagnostic Systems2003-02-28490

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda